Last reviewed · How we verify

Chronic hormonal treatment

Bayer · Phase 2 active Small molecule

Chronic hormonal treatment is a Small molecule drug developed by Bayer. It is currently in Phase 2 development. Also known as: 1. Mirena (Levonorgestrel - IUS), 2. Qlaira (Estradiol valerate and dienogest), 3. Progevera (Medroxyprogesterone acetate), and any new hormonal treatment marketed in Spain that has the indication for HMB.

At a glance

Generic nameChronic hormonal treatment
Also known as1. Mirena (Levonorgestrel - IUS), 2. Qlaira (Estradiol valerate and dienogest), 3. Progevera (Medroxyprogesterone acetate), and any new hormonal treatment marketed in Spain that has the indication for HMB
SponsorBayer
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chronic hormonal treatment

What is Chronic hormonal treatment?

Chronic hormonal treatment is a Small molecule drug developed by Bayer.

Who makes Chronic hormonal treatment?

Chronic hormonal treatment is developed by Bayer (see full Bayer pipeline at /company/bayer).

Is Chronic hormonal treatment also known as anything else?

Chronic hormonal treatment is also known as 1. Mirena (Levonorgestrel - IUS), 2. Qlaira (Estradiol valerate and dienogest), 3. Progevera (Medroxyprogesterone acetate), and any new hormonal treatment marketed in Spain that has the indication for HMB.

What development phase is Chronic hormonal treatment in?

Chronic hormonal treatment is in Phase 2.

Related